Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.

ABSTRACT:

Background and objectives

There is renewed interest in adrenocorticotropic hormone (ACTH) for the treatment of nephrotic syndrome. We evaluated the efficacy and safety of ACTH in children with frequently relapsing or steroid-dependent nephrotic syndrome in a randomized trial.

Design, setting, participants, & measurements

Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment. ACTH treatment regimen was 80 U/1.73 m² administered twice weekly for 6 months, followed by 40 U/1.73 m² administered twice weekly for 6 months. The primary outcome was disease relapse during

SUBMITTER: Wang CS 

PROVIDER: S-EPMC6302334 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature